Also considered
16 papers judged, 7 emailed · Read the digest →
Randomized phase 2 (RELATIVITY-104) in first-line stage IV/recurrent NSCLC, published in Annals of Oncology. Adding relatlimab to nivolumab plus chemotherapy did not meet the primary response endpoint, though a possible signal emerged in PD-L1 ≥1% nonsquamous disease, which is hypothesis-generating.
Phase 3 open-label RCT in EGFR-mutant advanced NSCLC with MET overexpression/amplification after osimertinib progression, published in NEJM. The combination improves progression-free survival over platinum-pemetrexed, supporting a biomarker-directed post-osimertinib option.
Phase 3 randomized open-label trial in extensive-stage SCLC without progression after first-line chemoimmunotherapy, published in NEJM. Adding tarlatamab to durvalumab maintenance improves overall survival at interim analysis, potentially changing first-line maintenance practice.
Phase 3 open-label RCT in untreated PD-L1-negative nonsquamous NSCLC without targetable alterations, published in NEJM. The ADC plus pembrolizumab markedly improves progression-free survival over chemotherapy plus pembrolizumab, suggesting a new first-line option pending survival data.
Phase 3 open-label RCT in previously treated KRAS G12C-mutated advanced NSCLC, published in NEJM. Divarasib improves progression-free and overall survival over first-generation KRAS G12C inhibitors, positioning it as a potential preferred agent.
Phase 1/2 first-in-class bispecific T cell agonist (invikafusp alfa) monotherapy trial in mostly ICB-resistant solid tumors, published in Nature Medicine. Shows manageable safety and responses in immunologically cold tumors such as MSS colorectal cancer and PD-L1-negative NSCLC, supporting further development.
Randomized, noncomparative phase 2 trial of serial ctDNA profiling with molecular tumor board review in first-line advanced NSCLC, published in Clinical Cancer Research. It was feasible and improved genotyping success, but clinical benefit was not shown, and ctDNA kinetics need validation in interventional trials.
Narrative review of multi-omics liquid biopsy for leptomeningeal metastases in lung cancer, published in Lung Cancer. Summarizes CSF ctDNA and CTC assays as more sensitive than cytology for diagnosis and monitoring, informing molecular assessment in this complication.
Cohort study of long-term outcomes with de-escalated elective nodal radiation during definitive chemoradiotherapy in HPV-associated oropharyngeal cancer, published in JAMA Oncology. Supports radiation de-escalation as a feasible approach, though non-randomized evidence.
Single-arm phase 2 trial of response-adapted, reduced-volume surgery following neoadjuvant immunochemotherapy in locally advanced HPV-negative head and neck squamous cell carcinoma, published in Clinical Cancer Research. Suggests a strategy to de-escalate surgery in strong responders while maintaining good outcomes, informing but not yet defining standard practice.
News/commentary in Cancer Discovery on a phase II/III trial of an HPV16 mRNA vaccine in head and neck cancer that failed to significantly delay progression. Suggests shared-antigen vaccines need better patient selection and OS-based evaluation, but doesn't change practice.
Retrospective multicenter genomic study of NSCLC patients, published in J Thorac Oncol, characterizing the prevalence and co-mutation profile of TP53 Y220C. Supports screening for this mutation and enrolling patients in future trials of Y220C reactivators.
Commentary on a single-institution phase 2 study (REMATCH) of reduced-volume surgery in locally advanced head and neck cancer responding to neoadjuvant immunochemotherapy, published in Clin Cancer Res. Suggests organ preservation is feasible by de-escalating local therapy, though it needs confirmation in larger trials.
Preclinical and cohort-based translational study of resistance to tarlatamab in DLL3-high small cell lung cancer, published in Cancer Cell. Identifies a serotonin-HTR7 macrophage axis as a potential target to improve T cell engager efficacy, but remains hypothesis-generating.
Prospective observational phase 4 real-world study of lurbinectedin in previously treated small cell lung cancer, published in Lung Cancer. Supports effectiveness and acceptable safety in a diverse population, with lower response in patients with brain metastases and shorter survival in platinum-resistant disease.
Preclinical mechanistic study in small cell lung cancer models including patient-derived xenografts, published in Cell. Shows metabolic cell state determines ferroptosis versus apoptosis susceptibility and offers a rationale for future metabolic therapeutic strategies, without direct clinical application yet.